Results: In both analyses, compared with sequential iGlar + Lixi, iGlarLixi led to significantly greater HbA1c reductions with associated weight loss and significantly more patients reaching target HbA1c <53 mmol/mol despite lower insulin doses. Symptomatic hypoglycaemia rates were similar, despite greater HbA1c reductions with iGlarLixi. Lower rates of gastrointestinal adverse events were observed with iGlarLixi, probably as a result of the more gradual titration of Lixi with iGlarLixi.
The GLP-1RAs have complementary antidiabetic effects to basal insulin, providing a solid clinical rationale for the combination of these two medication classes. 2, 3 Long-acting GLP-1RAs increase glucosedependent insulin secretion to primarily reduce fasting plasma glucose (FPG), with more limited effects on postprandial plasma glucose (PPG)
excursions. By contrast, short-acting GLP-1RAs, such as lixisenatide (Lixi), primarily reduce PPG and prandial glucose excursions, with more limited effects on fasting and interprandial hyperglycaemia. 2 Shortacting GLP-1RAs have demonstrated a greater effect on delaying gastric emptying compared with long-acting GLP-1RAs 4, 5 ; both GLP-1RA types suppress glucagon release and induce satiety. 2 Single-pen-administered, titratable fixed-ratio combinations of a GLP-1RA and basal insulin were developed as the next logical step from previous experience using free or sequential combinations to simplify titration and administration. iGlarLixi is a titratable fixed-ratio combination of insulin glargine 100 U (iGlar) and the GLP-1RA Lixi.
The LixiLan-O study demonstrated that the use of this simultaneous iGlarLixi formulation significantly and meaningfully reduced HbA1c without weight gain compared with iGlar or Lixi alone in patients with T2D uncontrolled on OADs. 6 In a similar population of patients, the GetGoal Duo-1 study, using a sequential treatment with
Lixi added to short-term iGlar, achieved significant reductions in HbA1c, PPG and body weight compared with iGlar + injectable placebo. 7 In patients with long-standing uncontrolled T2D, the LixiLan-L trial demonstrated that simultaneous iGlarLixi was associated with significantly greater reductions in HbA1c and body weight compared with iGlar alone. 8 In a similar patient population, the GetGoal Duo-2 study
showed that sequential treatment intensification with Lixi, added on to long-term iGlar, led to non-inferior reductions in HbA1c vs active control with insulin glulisine once (basal-plus) or thrice (basal-bolus) daily. 9 These two treatment strategies, simultaneous and sequential, have not been tested, however, in head-to-head studies, and it is unclear whether a titratable fixed-ratio combination of a GLP-1RA and basal insulin, such as iGlarLixi, may provide greater efficacy and/or tolerability compared with the sequential combination of both drugs.
In the present paper, we report two exploratory, hypothesisgenerating analyses that used propensity-score matching to compare indirectly the outcomes of GetGoal Duo-1 with those of LixiLan-O, and the outcomes of GetGoal Duo-2 with those of LixiLan-L, owing to the similar patient populations of these phase III trials. Propensityscore matching is a well-established statistical approach and has been used to compare therapeutic outcomes indirectly in numerous clinical fields, including T2D, allowing better comparison of different study populations by minimizing confounding factors. [10] [11] [12] [13] [14] Aside from the obvious advantage of fixed-ratio combinations in terms of the ease and simplicity of a single injection, the aim of this exploratory indirect analysis was to provide preliminary evidence for any further efficacy or safety benefits in favour of the titratable fixed-ratio combination iGlarLixi vs the separate sequential administration of iGlar and Lixi.
| MATERIALS AND METHODS

| Trial designs
The full methodology of the GetGoal Duo-1 (NCT00975286) and
LixiLan-O (NCT02058147) phase III trials in insulin-naïve patients with oral-agent failure, and the GetGoal Duo-2 (NCT01768559) and LixiLan-L (NCT02058160) phase III trials in patients with basal insulin failure, have been described previously in detail. All trials included adult patients with T2D for at least 1 year at screening; patients from GetGoal Duo-1 and LixiLan-O were uncontrolled on OADs for at least 3 months, and patients from GetGoal Duo-2 and LixiLan-L were uncontrolled on basal insulin with or without OADs for at least 6 months. [6] [7] [8] [9] Study designs and key outcomes are summarized in Tables S1 and S2. 2.2 | Endpoints
| Efficacy outcomes
Efficacy outcomes analysed were as follows: HbA1c change from baseline, percentage of patients achieving HbA1c <53 mmol/mol (<7.0%), median time to achieve glycaemic control (HbA1c <53 mmol/mol), change from baseline in FPG, change from baseline in 2-hour PPG after a standardized meal, change from baseline in body weight, and insulin dose at treatment end. All efficacy endpoints were evaluated at trial end at week 24 (week 26 for GetGoal Duo-2) other than 2-hour PPG, which was assessed at week 30 (LixiLan-O and -L), week 24 (GetGoal Duo-1) or week 26 (GetGoal Duo-2). Propensity-score matching was carried out based on baseline covariates to minimize measured confounding factors. Covariates used were as follows: age; race; baseline body mass index; baseline HbA1c; baseline FPG; diabetes duration; and OAD/metformin usage. Patients were matched based on the logit of the propensity score using caliper widths equal to 0.2 of the pooled SD of the logit of the propensity score. 15 The logit of the propensity score was used because this quantity is more likely to be normally distributed. Using calipers of width equal to 0.2 of the pooled SD of the logit of the propensity score will eliminate~99% of the bias attributable to the measured confounders. 15, 16 Sex was not included as a covariate because the proportions of men and women were comparable between the studies and were therefore not considered in matching. After matching, the proportions of men and women in the studies were confirmed to remain balanced. Additionally, baseline 2-hour PPG was not included as a covariate as only 79 patients from GetGoal Duo-2 had 2-hour PPG measurement at baseline.
| Safety outcomes
Efficacy analyses were evaluated using the modified intention-totreat population, comprising all randomized patients with a baseline assessment and at least 1 post-baseline assessment of any efficacy variable, irrespective of compliance with the protocol and procedures.
The safety population was defined as all randomized patients who received at least 1 dose of study medication.
An analysis of covariance model was used with treatment groups (fixed-ratio combination; free combination), randomization strata of
and country as fixed effects, and baseline value as a covariate. Last observation carried forward data were used to impute missing data values. Time to glycaemic control was estimated using the KaplanMeier method and reported as medians, as time-to-event data are mostly highly skewed and involved censored data. 17 Corresponding P values were calculated using the log-rank test and hazard ratios (HRs) were calculated using a Cox regression model with treatment as the only factor. Statistical significance was set at P < 0.05.
| RESULTS
3.1 | Population characteristics after propensityscore matching
| Propensity-score-matched pairs
The LixiLan-O and GetGoal Duo-1 studies included patients with T2D
newly initiating basal insulin, and the LixiLan-L and GetGoal Duo-2 studies included patients with T2D who had inadequate control despite long-term basal insulin treatment and multiple OADs. Table 1 shows the baseline demographics and disease characteristics of the study populations after propensity-score matching, which resulted in analysis of 87 matched pairs from LixiLan-O (simultaneous administration; iGlarLixi) and GetGoal Duo-1 (sequential administration; iGlar + Lixi), and 241 matched pairs from LixiLan-L (simultaneous administration; iGlarLixi) and GetGoal Duo-2 (sequential administration; iGlar + Lixi).
| Screening and baseline characteristics
After propensity-score matching, the mean AE SD HbA1c at screening in LixiLan-O (iGlarLixi) and GetGoal Duo-1 (iGlar + Lixi) was 66.3 AE 7.6 mmol/mol (8.2% AE 0.7%) and 70.5 AE 8.4 mmol/mol (8.6% AE 0.8%), and after run-in at baseline was well matched at 60.7 AE 7.9 mmol/mol (7.7% AE 0.7%) and 60.9 AE 5.4 mmol/mol (7.7% AE 0.5%), respectively. Mean AE SD HbA1c at screening in LixiLan-L (iGlarLixi) and GetGoal Duo-2 (iGlar + Lixi) was 68.2 AE 6.8 mmol/mol (8.4% AE 0.6%) and 69.8 AE 7.9 mmol/mol (8.5% AE 0.7%), and at baseline after run-in was 62.3 AE 6.8 mmol/mol (7.9% AE 0.6%) and 62.4 AE 5.9 mmol/mol (7.9% AE 0.5%), respectively ( Table 1) .
As expected, patients in the basal insulin intensification analysis In total, 88.5% and 90.8% of propensity-score-matched patients receiving iGlarLixi (LixiLan-O) and iGlar + Lixi (GetGoal Duo-1) completed study treatment, respectively.
| LixiLan-O and GetGoal Duo-1: efficacy outcomes
Mean AE SD HbA1c at week 24 was 46.1 AE 8.0 mmol/mol (6.4% AE 0.7%) with iGlarLixi compared with 52.7 AE 8.3 mmol/mol 
3). Changes in FPG and
PPG from baseline to end of study are shown in Table S3 .
Weight reduction at week 24 was significantly greater with iGlarLixi compared with iGlar + Lixi, with a treatment difference of 1.3 kg (P = 0.01; Figure 1B ). In GetGoal Duo-1, for patients who had newly ini- Figure 1A ). In this analysis, 62%
and 33% of patients who received iGlarLixi and iGlar + Lixi, respectively, achieved the target of HbA1c <53 mmol/mol (<7.0%; P < 0.0001). The median time to achieve HbA1c <53 mmol/mol (<7.0%) was significantly shorter with iGlarLixi (85 days) vs iGlar + Lixi (192 days; P < 0.0001), and the likelihood of achieving glycaemic control was significantly higher with iGlarLixi vs iGlar + Lixi (HR 2.2, 95% CI 1.8, 2.8; Figure 2B ). Changes in FPG and PPG from baseline to end of study are shown in Table S3 .
Weight reductions were numerically greater with iGlarLixi at week 24 vs those at week 26 with iGlar + Lixi (−1.0 vs 0.6 kg; P = 0.38; Figure 1B ). The absolute mean insulin dose was higher at week 26 with iGlar + Lixi compared with iGlarLixi at week 24 ( Figure 1C) ; however, it should be noted that the absolute mean AE SD insulin dose also showed a significant difference at baseline (66 AE 32 vs 35 AE 9 U; P < 0.0001). The least squares (LS) mean AE SE change from baseline to end of study was 1 AE 1 U with iGlar + Lixi and 9 AE 1 U with iGlarLixi (LS mean AE SE difference, 8 AE 1 U; P < 0.0001).
| LixiLan-L and GetGoal Duo-2: safety outcomes
Serious AEs were experienced by 6.3% and 3.3% of patients in the iGlarLixi and iGlar + Lixi arms, respectively (Table 2) Abbreviations: AE, adverse event; iGlar, insulin glargine 100 U; Lixi, lixisenatide; RTI, respiratory tract infection. a n = 241 pairs were matched based on randomized patients regardless of their protocol adherence; however, 2 patients in the iGlarLixi cohort did not meet the safety population criteria (did not receive at least 1 dose of study drug). b Symptomatic hypoglycaemia was included in the AE listing for GetGoal Duo-1 and GetGoal Duo-2. c Preferred terms with occurrence ≥5% are shown.
FIGURE 3
Occurrence of symptomatic hypoglycaemia (safety population). Symptomatic hypoglycaemia defined as plasma glucose ≤3.9 mmol/L (≤70 mg/dL). iGlar, insulin glargine 100 U; Lixi, lixisenatide titration and lower drug doses at study end. 18, 19 Despite achieving greater HbA1c reductions with iGlarLixi, symptomatic hypoglycaemia was less frequent with iGlarLixi in LixiLan-O than with iGlar + Lixi in GetGoal Duo-1, and comparable with iGlarLixi and iGlar + Lixi in LixiLan-L and GetGoal Duo-2. Severe hypoglycaemia was uncommon.
The pathogenesis of T2D is multifactorial; thus, simultaneously targeting several of these mechanisms should provide greater benefits than addressing one at a time, and most guidelines are advocating for the early use of combination therapy. 20, 21 Guidelines suggest treating to target and intensifying therapeutic strategies if glycaemic goals are not achieved within a given timeframe 1, 20 ; however, longitudinal observational studies of electronic medical records from EU countries and the USA showed that failure to achieve target HbA1c early on (3-6 months) was associated with increased risk of failure to achieve glycaemic control. 22, 23 Patients who undergo treatment intensification at lower HbA1c levels are more likely to achieve HbA1c ≤53 mmol/ mol (≤7.0%) than patients whose treatment is intensified at higher levels of glycaemia. 24 Furthermore, patients who receive early treatment intensification achieve treatment goals more rapidly than those who do not, regardless of the target HbA1c level. 25 Notably, in both 
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